Read More

The Week Ahead In Biotech: Earnings Kickstart With J&J And Biogen, Albireo Awaits FDA Decisions, More IPOs

Biotech stocks were down for a second week in a row, as they retreated along with the broader market amid macro concerns. Consumer price inflation data released during the week stoked rate hike fears, and exerted negative pressure on stocks. There were very few stock-specific catalysts, barring a few preannouncements, stock offerings, and a slew of initial public offerings.

ABT

Read More

What 3 FibroGen Analysts Are Expecting From Thursday’s Roxadustat Adcom Verdict

FibroGen, Inc. (NASDAQ: FGEN) has a key catalyst Thursday when FDA's Cardiovascular and Renal Drugs Advisory Committee will issue its recommendation on the company's new drug application for roxadustat. The committee is scheduled to meet between 9:30 a.m. and 5:30 p.m.

AZN